mRNA overexpression of BAALC: A novel prognostic factor for pediatric acute lymphoblastic leukemia

ZAHRA AZIZI1, SOHEILA RAHGOZAR1, ALIREZA MOAFI2, MOHAMMAD DABAGHI1 and MOTAHAREH NADIMI1

1Division of Cell, Molecular and Developmental Biology, Department of Biology, Faculty of Science, University of Isfahan, Isfahan 81746-73441; 2Department of Pediatric Hematology Oncology, Sayed Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan 81856-66153, Iran

Received January 28, 2015; Accepted February 20, 2015

DOI: 10.3892/br.2015.437

Abstract. BAALC is a novel molecular marker in leukemia that is highly expressed in patients with acute leukemia. Increased expression levels of BAALC are known as poor prognostic factors in adult acute myeloid and lymphoid leukemia. The purpose of the present study was to evaluate the prognostic significance of the BAALC gene expression levels in pediatric acute lymphoblastic leukemia (ALL) and its association with MDR1. Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), the mRNA expression levels of BAALC and MDR1 were measured in bone marrow samples of 28 new diagnosed childhood ALL patients and 13 children without cancer. Minimal residual disease (MRD) was measured one year after the initiation of the chemotherapy using the RT-qPCR method. The high level expression of BAALC had a significant association with the pre-B-ALL subtype, leukocytosis and positive MRD after one year of treatment in leukemic patients. In addition, a positive correlation between BAALC and MDR1 mRNA expression was shown in this group. In conclusion, to the best of our knowledge, the increase of BAALC expression as a poor prognostic factor for childhood ALL is shown for the first time. Additionally, the correlation between BAALC and MDR1 mRNA expression levels can aid for an improved understanding of the mechanism through which BAALC may function in ALL and multidrug resistance.

Introduction

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, responsible for 25-30% of all cancers in children <15 years (1-2). Although the complete remission of this disease is ~70-80%, there remains the risk of relapse in 20-30% of these children (3-6). Resistance to chemotherapy considerably reduces the rate of treatment success and increases the risk of relapse (7-9).

The BAALC gene is a marker of hematopoietic precursor cells that was detected for the first time in adult acute myeloid leukemia (AML). The BAALC gene is located on chromosome 8q22.3 and is expressed in differentiated cells of the nervous system, neuroectoderm-derived tissues (10) and bone marrow hematopoietic precursor cluster of differentiation 34+ cells (11). Studies have shown that increased BAALC expression causes poor treatment results and resistance to chemotherapy in adult AML and ALL patients (12-14).

Adenosine triphosphate (ATP)-binding cassette sub-family B member (ABCB1), also known as multidrug resistance 1 (MDR1), is an ATP-dependent transporter that is responsible for inhibiting the accumulation of chemotherapy drugs in multidrug resistant cells (15-17). Increased expression levels of ABCB1 in children with ALL leads to a high risk of relapse (18-19). Studies show that the expression levels of the BAALC gene has a positive association with increased expression levels of ABCB1 in AML drug resistance. Additionally, the association of high mRNA expression levels of BAALC with increased levels of ABCB1 contributes to an increased risk of relapse in AML patients, as well as to a decreased rate of complete remission and worse overall survival rate in these patients (12-14). The present study is a novel investigation on BAALC that examines the mRNA expression levels of this gene in children with ALL and evaluates its association with ABCB1 and the response to therapy in these patients.

Materials and methods

Patients and sample preparation. Subsequent to obtaining fully informed consent from all the parents, 28 bone marrow samples from children <15 years of age (new case), including 5 cases of T-ALL and 23 cases of B-ALL, were studied and compared to 13 bone marrow samples of children with no cancer symptoms. The latter aforementioned samples were those investigated for autoimmune diseases. A total of 2 ml of bone marrow samples was obtained under general anesthesia, added to 0.1 ml heparin and sent to the laboratory on ice.
Mononuclear cell isolation was performed using Lymphoprep (Axis-Shiled Diagnostics Ltd., Oslo, Norway). Hematological indices were measured with automated analyzers (Technicon H1; Bayer Corp, Etobicoke, ON, Canada).

**mRNA isolation and assessment.** Total RNA isolation from mononuclear cells was carried out using the RNaseasy Mini kit (Qiagen, Hilden, Germany). The amount and quality of extracted RNA was measured by a BioPhotometer (Eppendorf AG, Hamburg, Germany) and the extracted RNA samples were loaded on 1.8% agarose gel (Merck KGaA, Darmstadt, Germany) for quality assessment. Subsequently, 2 µg total RNA was converted to cDNA using a cDNA synthesis kit and random hexamer primers (Fermentas, St. Leon-Rot, Germany). The housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*), was selected as an internal control. Specific forward primers for *BAALC*, *ABCB1* and *GAPDH* genes were 5'GCCCTCTGACCCAGAACAGA3', 5'GAGGCCGCTGTTCGTTTCCTTTAGGTC3' and 5'GCCCCAGCAAGAGCACAAGAGGAAAGA3', respectively. Reverse primers for the abovementioned genes were 5'CTTTTGGACGCTTCTCTTAGCA3', 5'AGATTTACTGAGACCTCGCGCTCCT3' and 5'CATGGCAACTGTGGAGGGGAGAT3', respectively. SYBER Premix Ex Taq II Real Time kit (Takara Bio, Inc., Tokyo, Japan) was used for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) that was carried out through an optimized program (3-5 min pre-incubation at 95˚C, 10-15 sec denaturation at 95˚C, 30 sec annealing at 59-61˚C and 30 sec product expansion at 72˚C in 35-45 cycles). Correlations were investigated between the *BAALC* and *ABCB1* mRNA expression levels. Any association between the *BAALC* gene expression levels and certain prognostic factors of childhood ALL, including age, white blood cell (WBC) counts, platelet counts and hemoglobin levels, were also examined at the onset of the disease.

**Evaluation of treatment response.** Newly diagnosed patients were treated based on the Australian and New Zealand Children’s Cancer Study Group ALL study 8 protocol (http://www.anzctr.org.au/trial_view.aspx?ID=1568). To assess treatment response in the year following the initiation of the treatment, the amount of minimal residual disease (MRD) was studied using RT-qPCR to detect monoclonal immunoglobulin heavy chain gene rearrangement. Persistence of monoclonality, referred to as MRD+, was considered as a poor response to therapy and drug resistance.

**Statistical analysis.** Statistical analysis was performed using the Graphpad Prism 5 software. Correlations between gene expression levels and ALL prognostic factors were measured using Pearson and Spearman’s correlation tests. Association between gene expression and response to therapy was performed using Fisher’s exact test. Data are shown as mean ± standard error of the mean (SEM) and P≤0.05 was considered to indicate a statistically significant difference.

**Results**

**Patients.** A total of 28 patients were involved in the study. One of the patients succumbed during the induction stages due to infection. Two patients, who relapsed during the first year of treatment, were considered as treatment resistant patients. The remaining 25 patients were investigated for signs of MRD at the end of the first year of chemotherapy. Monoclonality remained persistent for 6 patients who were considered MRD+ and resistant to therapy.

**mRNA expression levels of the *BAALC* gene.** The mRNA expression levels of *BAALC* were significantly different between *de novo* patients and the control group (mean ± SEM, 3.67±0.66 vs. 1.24±0.27, respectively; P=0.04) (Fig. 1).

The comparison of the *BAALC* gene expression level between the ALL subgroups (T-ALL, early pre-B cell and pre B-cell) showed a significant difference only for early pre-B cell subtype compared to the control group (mean ± SEM, 3.52±1.56 vs. 1.24±0.27, respectively; P=0.03) (Fig. 2).
and several prognostic factors in childhood ALL, including age, WBC counts, platelet counts and hemoglobin levels, were investigated. Spearman's correlation tests demonstrated a significantly positive correlation between the mRNA expression levels of BAALC and WBC count in childhood ALL (P=0.04). There was no significant correlation between the increased expression levels of BAALC and age (P=0.41), gender (P=0.40), platelet count (P=0.31) and hemoglobin levels (P=0.18).

Table I. Association between the BAALC expression levels and response to therapy.

<table>
<thead>
<tr>
<th>Cut-off point for BAALC expression</th>
<th>MRD⁺</th>
<th>MRD⁻</th>
<th>P-value</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;2-fold</td>
<td>7</td>
<td>4</td>
<td>0.001</td>
<td>4.14</td>
</tr>
<tr>
<td>&lt;2-fold</td>
<td>4</td>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MRD, minimal residual disease.

**Discussion**

To the best of our knowledge, the present study identifies the role of BAALC as a prognostic biomarker in childhood ALL for the first time. In addition, the data showed that BAALC gene expression in de novo patients is 2.4 times more than in the control group. However, we do not believe that BAALC may be considered as a valuable diagnostic factor for ALL, as BAALC gene overexpression is reported only in immature cells that were increased primarily at the onset of the disease prior to sampling (11,20-21). What makes this phenotype more clinically important is the uneven overexpression of the gene in different leukemic blast cells. The present results indicate a significant increase in mRNA expression levels of BAALC in MRD⁺ patients compared to the control group, which indicates that the immature cells expressing more of the BAALC gene are the more resistant cells to chemotherapy. These data suggest that BAALC has an adverse impact on response to therapy. Therefore, increased expression of BAALC is introduced as a poor prognostic factor for childhood ALL. The first studies to validate the poor prognostic value of BAALC were performed in adult leukemic patients or children with AML (14,22-24). These studies indicate an association between the increased mRNA expression levels of BAALC with poor treatment response and early drug resistance. Consequently, BAALC is proposed as a risk factor for adult leukemia patients (13-14,21). These findings are consistent with the present study, demonstrating that the 2-fold increase of BAALC expression in MRD⁺ patients compared to normal levels may elevate the risk of relapse by 4.14 times. These findings allow for the development of improved therapies. By contrast, the present study may open up more opportunities to understand the multifactorial pathophysiology of ALL.

The pathophysiological role of BAALC is under investigation. However, the precise function of this protein in cancer biology has remained undefined. High expression levels of BAALC are reported to increase proliferation and decrease apoptosis in leukemic cell lines (25). By contrast, it is suggested that BAALC may have an impact on multidrug resistance through association with the ABC transporters in AML. The present study has examined, for the first time, the association between BAALC and ABCB1, one member of this large family, in childhood ALL. The mRNA expression profile of ABCB1 in childhood ALL was recently studied by our group and was suggested to be a risk factor for treatment failure and multidrug resistance in this disease (18-19). Our findings show that the increase of BAALC expression is positively associated with ABCB1 mRNA expression profiles. However, it is unclear whether these two genes are expressed dependently, or that they are two separate prognostic factors that function in
different pathways. The mechanism by which these two genes operate awaits further confirmation.

Cytogenetic studies were not available in the present study, however, statistical tests were performed to investigate the association between BAALC mRNA expression levels and several clinical characteristics, including gender, WBC and platelet counts, hemoglobin levels and serum biochemistries such as lactate dehydrogenase. Results showed that among the aforementioned ALL risk factors, high BAALC expression mRNA levels were solely associated with the increased numbers of WBCs >50x10^9/µl at the time of diagnosis. This association is supported by the potential role of BAALC in leukemia cells proliferation and resistance to apoptosis, which was previously mentioned in this section.

In conclusion, BAALC mRNA overexpression is proposed as a negative prognostic factor in childhood ALL, which increases the risk of resistance to chemotherapy. It is suggested elsewhere that BAALC may promote leukemic cell proliferation and inhibit their apoptosis. The present results show that simultaneous overexpression of BAALC and ABCB1 in MRD+ children with ALL may introduce a second mechanism through which BAALC may apply its adverse effect on response to treatment. The exact function of BAALC in childhood ALL and the manner of its communication with ABC transporters for increasing the risk of resistance to therapy remain to be established.

References